#3347 COVID VACCINE RESPONSES DURING SIBEPRENLIMAB TREATMENT OF IGA NEPHROPATHY (IGAN): AN INTERIM ANALYSIS
Kieran McCafferty(Queen Mary University of London), Yusuke Suzuki(Juntendo University), Frank Engler(Certara (United States)), Kristin Follman(Certara (United States)), Mallory Shriver(University of Maryland, Baltimore), Marcela F. Pasetti(University of Maryland Global Campus), Diane MA(Visterra (United States)), Jill Yarbrough(Visterra (United States)), David Oldach(Visterra (United States)), Mohit Mathur(John Hunter Hospital), Asher D. Schachter(Visterra (United States))
Cited by 6
Related Papers
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
|Kidney International|2021|2.5k
Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group
|Kidney International|2017|1.2k
Human Decidual Natural Killer Cells Are a Unique NK Cell Subset with Immunomodulatory Potential
|The Journal of Experimental Medicine|2003|897
Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases
|Kidney International|2021|809